Advertisement
APVO vs GOSS
Which Stock Would AI Choose? Aptevo Therapeutics (APVO) vs. Gossamer Bio (GOSS) Stock Comparison
Key Takeaways
- Both APVO and GOSS are clinical-stage biotechnology companies with no commercial product revenue, making them high-risk, catalyst-driven names.
- Aptevo is focused on oncology immunotherapy, led by mipletamig for acute myeloid leukemia (AML), while Gossamer is centered on seralutinib for pulmonary arterial hypertension (PAH).
- Gossamer's Phase 3 PROSERA trial missed its primary statistical threshold in early 2026, triggering an approximate 80% single-session share decline and a subsequent reverse stock split.
- Aptevo has reported encouraging early AML data but trades near multi-year lows, with a market capitalization of only a few million dollars.
- Both stocks face substantial dilution and cash-runway risk, though each retains analyst price targets implying significant theoretical upside.
- For a deeper look, explore APVO Major News and APVO Today's Price Move, along with GOSS Major News and GOSS Today's Price Move.
- To see how quantitative models are currently positioning across the market, explore Trending AI Robots.
Introduction
Investors tracking small-cap biotechnology often weigh companies whose share prices no longer reflect their clinical pipelines. APVO (Aptevo Therapeutics) and GOSS (Gossamer Bio) both fit that profile, having experienced severe price compression despite ongoing drug-development programs. This stock comparison is most relevant for risk-tolerant traders and investors who follow binary clinical catalysts, reverse splits, financing events, and sentiment shifts. Because both companies are pre-revenue and heavily dependent on trial results, their relative performance and market positioning hinge on factors that differ from mature biopharmaceutical firms.
APVO Overview and Recent Performance
APVO, or Aptevo Therapeutics, is a clinical-stage biotechnology company developing bispecific and trispecific immunotherapies for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX platforms. Its lead candidate, mipletamig, is being evaluated in the Phase 1b/2 RAINIER trial for frontline acute myeloid leukemia (AML), a blood cancer. In recent weeks, the company reported that ten AML patients advanced to allogeneic stem cell transplant, a favorable outcome, and highlighted a 93% clinical benefit rate in a difficult-to-treat TP53-mutated subgroup. Aptevo has also advanced next-generation trispecific candidates toward clinical development and disclosed a radiopharmaceutical collaboration with Niowave. Despite these developments, the stock trades near multi-year lows and its market capitalization has shrunk to only a few million dollars, reflecting persistent execution and financing concerns. Cash and equivalents totaled roughly $14.5 million as of late Q1 2026, with the company relying on equity financing arrangements to fund operations.
GOSS Overview and Recent Performance
GOSS, or Gossamer Bio, is a clinical-stage biopharmaceutical company focused on seralutinib for the treatment of pulmonary arterial hypertension (PAH). In early 2026, the company disclosed that its Phase 3 PROSERA study missed its prespecified statistical threshold, with a placebo-adjusted six-minute walk distance improvement that did not reach the required significance level. The news triggered a sharp selloff and was followed by a 1-for-80 reverse stock split, multiple analyst downgrades, and a securities class action. In response, Gossamer narrowed its strategic focus to PAH, paused a related program, and announced plans to pursue a New Drug Application (NDA) submission. The company reported roughly $99 million in cash as of late Q1 2026, with a runway into early 2027, and proposed an exchange of convertible notes to reduce debt. These restructuring steps have shaped a volatile, event-driven trading profile in recent months.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's automated trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, yet only those best suited to current market conditions earn a place in this featured section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the sets of tickers they follow, allowing users to identify approaches aligned with their own risk preferences. Because the list is updated to reflect prevailing market dynamics, it offers a practical starting point for traders evaluating systematic strategies. Explore the Trending AI Robots to review the latest selections.
Head-to-Head Comparison
The two companies occupy different therapeutic niches but share structural similarities. APVO is oriented toward oncology, where a broad patient population and multiple pipeline candidates provide diversification but also raise development complexity. GOSS is effectively a single-asset story built around seralutinib, concentrating both upside and downside in one regulatory pathway. On recent momentum, both have been weak, though their catalysts differ: Aptevo's near-term value rests on continued AML data and dose selection, while Gossamer's hinges on its planned NDA submission and any regulatory feedback. Risk factors also diverge, with Gossamer carrying convertible-debt obligations and litigation exposure, whereas Aptevo faces dilution from equity financing arrangements. Neither generates product revenue, so market sentiment is driven primarily by trial readouts and capital-position announcements rather than fundamentals.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely lean cautiously toward APVO over GOSS in the current environment. Aptevo's catalysts appear more diversified across an oncology pipeline, and its recent clinical disclosures have been directionally positive even as the share price has lagged. Gossamer, by contrast, is recovering from a failed primary endpoint, a reverse split, analyst downgrades, and litigation, all of which introduce greater headline-driven volatility. That said, both names remain speculative and distressed, and any relative edge is probabilistic rather than definitive. A systematic approach would likely favor the candidate with more stable trend characteristics and a broader set of near-term catalysts while continuing to monitor financing risk closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APVO is a Hold and GOSS is a Hold.
APVO sees MACD Histogram just turned negative
APVO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 41 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for APVO entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where APVO advanced for three days, in 141 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
APVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.366) is normal, around the industry mean (3.498). P/E Ratio (0.003) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. APVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
GOSS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for GOSS turned positive on October 12, 2026. Looking at past instances where GOSS's MACD turned positive, the stock continued to rise in 34 of 38 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on GOSS as a result. In 64 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +15.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where GOSS advanced for three days, in 214 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 48 cases where GOSS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GOSS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
GOSS broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GOSS entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.636) is normal, around the industry mean (3.498). P/E Ratio (-0.230) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.666) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. GOSS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GOSS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
APVO | GOSS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 21 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 33 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 95 | 65 | |
P/E GROWTH RATING 1..100 | 97 | 28 | |
SEASONALITY SCORE 1..100 | n/a | 48 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GOSS's Valuation (33) in the Pharmaceuticals Major industry is in the same range as APVO (52) in the Biotechnology industry. This means that GOSS’s stock grew similarly to APVO’s over the last 12 months.
GOSS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as APVO (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to APVO’s over the last 12 months.
GOSS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as APVO (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to APVO’s over the last 12 months.
GOSS's Price Growth Rating (65) in the Pharmaceuticals Major industry is in the same range as APVO (95) in the Biotechnology industry. This means that GOSS’s stock grew similarly to APVO’s over the last 12 months.
GOSS's P/E Growth Rating (28) in the Pharmaceuticals Major industry is significantly better than the same rating for APVO (97) in the Biotechnology industry. This means that GOSS’s stock grew significantly faster than APVO’s over the last 12 months.
| APVO | GOSS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | N/A |
| Stochastic ODDS (%) | N/A | 2 days ago 90% |
| Momentum ODDS (%) | N/A | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Advances ODDS (%) | 8 days ago 76% | 2 days ago 85% |
| Declines ODDS (%) | 2 days ago 90% | 9 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APVO’s FA Score shows that 0 FA rating(s) are green while GOSS’s FA Score has 2 green FA rating(s).
- APVO’s FA Score: 0 green, 5 red.
- GOSS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APVO’s TA Score shows that 3 TA indicator(s) are bullish while GOSS’s TA Score has 3 bullish TA indicator(s).
- APVO’s TA Score: 3 bullish, 3 bearish.
- GOSS’s TA Score: 3 bullish, 4 bearish.
Price Growth
APVO (@Biotechnology) experienced а -20.59% price change this week, while GOSS (@Biotechnology) price change was +21.55% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
APVO is expected to report earnings on Nov 12, 2026.
GOSS is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
GOSS and
Correlation & Price change
A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with LITS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then LITS could also see price increases.
| Ticker / NAME | Correlation To GOSS | 1D Price Change % | ||
|---|---|---|---|---|
| GOSS | 100% | +5.97% | ||
| LITS - GOSS | 46% Loosely correlated | +0.86% | ||
| APVO - GOSS | 41% Loosely correlated | -4.42% | ||
| IDYA - GOSS | 38% Loosely correlated | -0.87% | ||
| XNCR - GOSS | 38% Loosely correlated | +2.07% | ||
| SYRE - GOSS | 38% Loosely correlated | -4.15% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GDOC | 39.41 | N/A | N/A |
| Future Health Care Equity ETF (GDOC) | |||
| EVHY | 51.16 | -0.07 | -0.13% |
| Eaton Vance High Yield ETF (EVHY) | |||
| TACK | 31.80 | -0.20 | -0.62% |
| Fairlead Tactical Sector ETF (TACK) | |||
| FIYY | 23.96 | -0.17 | -0.70% |
| GraniteShares YieldBOOST 20Y+ Treasuries ETF (FIYY) | |||
| LTPZ | 46.14 | -0.83 | -1.77% |
| PIMCO 15+ Year US TIPS Index Exchange-Traded Fund (LTPZ) | |||